drug: naltrexone
- Clinical class: anti-alcoholic, opioid dependence treatment adjunct
- Action: opioid antagonist
- Active metabolite: 6β naltrexol
- CSA schedule: none
- DEA number: none
- MEDLINEplus® Drug Information
U.S. Preparations:
- Depade® (Mallinckrodt) FDA
approved:
3.2.2002 for treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids
12.2006 ceased production
Prescribing Information
- Naltrel™ (DrugAbuse Sciences) in development
- ReVia® (DuPont Pharma) FDA approved for treatment of: narcotic and alcohol dependence
- Trexan® (archaic)
- Trexonil® (veterinary, Wildlife Pharmaceuticals) FDA approved for treatment of : not approved for human use
- Vivitrol™ (previously Vivitrex®) (Alkermes, Cephalon) FDA
approved:
4.13.2006 for treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with Vivitrol™
Prescribing Information - generic
Foreign Preparations:
- Antaxone, Celupan, Nalorex, Narcoral, Nemexin